TP53 and acute myeloid leukemia: An ongoing trial will evaluate TTI-622 in combination with azacitidine for patients with TP53m-AML and in combination with azacitidine + venetoclax in patients with TP53 wild-type AML, both starting at a TTI-622 dose of 8 mg/kg (NCT03530683) [102].